In search of effective therapies to overcome resistance to Temozolomide in brain tumours

Abstract

Glioblastoma multiforme is the most common and lethal brain tumour-type. The current standard of care includes Temozolomide (TMZ) chemotherapy. However, inherent and acquired resistance to TMZ thwart successful treatment. The direct repair protein methylguanine DNA methyltransferase (MGMT) removes the cytotoxic O6-methylguanine (O6-MeG) lesion delivered by TMZ and so its expression by tumours confers TMZ-resistance. DNA mismatch repair (MMR) is essential to process O6-MeG adducts and MMR-deficiency leads to tolerance of lesions, resistance to TMZ and further DNA mutations. In this article, two strategies to overcome TMZ resistance are discussed: (1) synthesis of imidazotetrazine analogues - designed to retain activity in the presence of MGMT or loss of MMR; (2) preparation of imidazotetrazine-nanoparticles to deliver TMZ preferably to the brain and tumour site. Our promising results encourage belief in a future where better prognoses exist for patients diagnosed with this devastating disease.

Keywords

Brain cancer / temozolomide-resistance / analogues / drug delivery / apoferritin

References

[1] Parsons D,Zhang X,Leary R.An integrated genomic analysis of human glioblastoma multiforme..Science2008;321:1807-12 PMCID:PMC2820389

[2] Philips H,Chen R,Soriano R.Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis..Cancer Cell2006;9:157-73

[3] Beroukhin R,Nghiemphu L,Hsueh T.Assessing the significance of chromosomal aberrations in cancer: metodology ad application to glioma..PNAS2007;104:20007-12 PMCID:PMC2148413

[4] Karcher S,Ahmadi R,Vasvari G.Different angiogenic phenotypes in primary and secondary glioblastomas..Int J Cancer2006;118:2182-9

[5] Scherer H.The forms of growth in gliomas and their practical significance..Brain1940;63:1-35

[6] Smith C,Schiapparelli P,Kim D.Migration phenotype of brain-cancer cells predicts patient outcomes.Cell Reports2016;15:2616-24 PMCID:PMC5517094

[7] Brodbelt A,Winters T,Vernon S.Glioblastoma in England: 2007-2011..Eur J Cancer2015;51:533-42

[8] Abbott NJ,Dolman DE,Begley DJ.Structure and function of the blood-brain barrier..Neurobiol Dis2010;37:13-25

[9] Wang Z,Yakisich JS.Overcoming the blood-brain barrier for chemotherapy: limitations, challenges and rising problems..Anticancer Agents Med Chem2014;14:1085-93

[10] Groothuis D.The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery..Neuro-Oncology2000;2:45-59 PMCID:PMC1920694

[11] Newlands ES,Slack JA,Smith DB.Phase I trial of temozolomide (CCRG 81045:M&B 39831: NSC 362856)..Br J Cancer1992;65:287-91 PMCID:PMC1977719

[12] Denny BJ,Stevens MGF,Slack JA.NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.Biochemistry1994;33:9045-51

[13] Tisdale MJ.Antitumor imidazotetrazines - XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones..Biochem Pharmacol1987;36:457-62

[14] Hegi M,Gorlia T,de Tribolet N.MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma..N Engl J Med2005;352:997-1003

[15] Zhang J,Laughton CA,Bradshaw TD.Acquired resistance to Temozolomide in glioma cell lines: molecular mechanisms and potential translational applications..Oncology2010;78:103-14

[16] Zhang J,Bradshaw TD.Temozolomide: mechanisms of action, repair and resistance..Curr Mol Pharmacol2012;5:102-14

[17] Wiewrodt D,Dreimuller N,Perneczky A.MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome..Int J Cancer2008;122:1391-9

[18] Kitange G,Schroder M,Lamont J.Induction of MGMT expression is associated with temozolomide resistance in gliobastoma xenografts..Neuro-Oncology2009;11:281-91 PMCID:PMC2718972

[19] Zhang J,Matthews CS,Bradshaw TD.N3-Substituted temozolomide analogues overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death..Oncology2015;88:28-48

[20] Poulogiannis G,Arends MJ.DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome..Histopathology2010;56:167-79

[21] Cahill DP,Batchelor TT,Louis DN.MSH6 inactivation and emergent temozolomide resistance in human glioblastomas..Clin Neurosurg2008;55:165-71

[22] Yip S,Cahill DP,Aldape K.MSH6 mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance.Clin Cancer Res2009;15:4622-9 PMCID:PMC2737355

[23] Hunter C,Cahill DP,Stevens C.A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy..Cancer Res2006;66:3987-91

[24] Daniel P,Chaddad A,Jean-Claude B.Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities..Front Oncol2019;9:41 PMCID:PMC6369148

[25] Calatozzolo C,Ciusani E,Pollo B.Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma..J Neurooncol2005;74:113-21

[26] Balesaria S,Bower M,Nicholson SK.Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas..British J Cancer1999;81:1371-7 PMCID:PMC2362970

[27] Lefranc F,DeWitte O.Present and potential future adjuvant issues in high-grade astrocytic glioma treatment..Adv Tech Stand Neurosurg2009;34:3-35

[28] Bax DA,Gaspar N,Marshall L.Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development..PLoS One2009;4:e5209 PMCID:PMC2666263

[29] Gaspar N,Perryman L,Little SE.MGMT-Independent Temozolomide resistance in paediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/STEM cell gene signature..Cancer Res2010;70:9243-52 PMCID:PMC3935452

[30] Molenaar RJ,Wilmink JW.Wild-type and mutated IDH1/2 enzymes and therapy responses..Oncogene2018;37:1949-60 PMCID:PMC5895605

[31] Lu Y,Liu Y,Frady LN.Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair..Cancer Res2017;77:1709-18 PMCID:PMC5380481

[32] Plummer R,Middleton M,Evans J.Phase I study of the poly(ADP-Ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors..Clin Can Res2008;14:7917-23 PMCID:PMC2652879

[33] Cao X,Liu Y,Song H.Combination of PARP inhibitor and temozolomide to suppress chordoma progression..J Mol Med (Berl)2019;97:1183-93

[34] Zhang J,Hummersone M,Laughton CA.Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair..Oncology2011;80:195-207

[35] Cousin D,Bradshaw TD,Moody CJ.Synthesis and growth inhibitory activities of imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon benzyl and heteromethyl groups at the 3-position..MedChemComm2018;19;9:545-53 PMCID:PMC6072467

[36] Othman RT,Bradshaw TD,Korshunov A.Overcoming multiple drug resistance mechanisms in medulloblastoma..Acta Neuropath Comm2014;2:57 PMCID:PMC4229867

[37] Cousin D,Hummersone MG,Frigerio M.Antitumor Imidazo[5,1-d]-1,2,3,5-tetrazines: compounds modified at the 3-position overcome Resistance in human glioblastoma cell lines..MedChemComm2016;7:2332-43

[38] Svec RL,Skibinski CG,Riggins GJ.Tunable stability of imidazotetrazines leads to a potent compound for glioblastoma..ACS Chem Biol2018;13:3206-16 PMCID:PMC6243397

[39] Yang Z,Dai X,Bradshaw TD.C8-Substituted imidazotetrazine analogs overcome temozolomide resistance by inducing DNA adducts and DNA damage..Front Oncol2019;9:485 PMCID:PMC6584802

[40] Summers H. Synthesis and biological evaluation of novel imidazotetrazines PhD thesis 2019, University of Nottingham

[41] Oberoi R,Sio T,Elmquist W.Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma..Neuro-Oncology2015;18:27-36 PMCID:PMC4677418

[42] Kim J,Kim Y.Nanotherapeutics engineered to cross the bllo-brain barrier for advanced drug delivery to the central nervous system..J Industrial and Eng Chem2019;73:8-18 PMCID:PMC6777578

[43] Ostermann S,Buclin T,Lejeune F.Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients..Clin Can Res2004;10:3728-36

[44] Portnow J,Chen M,Blanchard S.The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation..Clin Cancer Res2009;15:7092-8 PMCID:PMC2908372

[45] Thiel EC.Ferritin: structure, gene regulation, and cellular function in animals, plants and microorganisms..Annu Rev Biochem1987;56:289-315

[46] Heger Z,Zitka O,Kizek R.Apoferritin applications in nanomedicine..Nanomedicine (Lond)2014;9:2233-45

[47] Monti DM,Merlino A.Ferritin-based anticancer metallodrug delivery: Crystallographic, analytical and cytotoxicity studies..Nanomedicine NBM2019;20:101997

[48] Li L,Ryan J,Lebrón J.Binding and uptake of H-ferritin are mediated by human transferrin receptor-1..PNAS2010;107:3505-10 PMCID:PMC2840523

[49] Torti S.Iron and cancer: more ore to be mined..Nature Rev Cancer2013;13:342-55 PMCID:PMC4036554

[50] Hulet SW,Connor JR.Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains..J Neurol Sci1999;165:48-55

[51] Jeffries W,Hunt S,Gatter K.Transferrin receptor on endothelium of brain capillaries..Nature1984;312:162-3

[52] Rosager A,Dahlrot R,Schonberg D.Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors. Expression and prognostic value..PLoS One2017;12:e0182954 PMCID:PMC5570299

[53] Johnsen KB,Melander F,Vejlebo JB.Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma..Sci Rep2017;7:10396 PMCID:PMC5583399

[54] Duck KA.Iron uptake and transport across physiological barriers..Biometals2016;29:573-91 PMCID:PMC4972853

[55] Todorich B,Connor JR.H-Ferritin is the major source of iron for oligodendrocytes..Glia2011;59:927-35

[56] Cordon-Cardo C,Casals D,Biedler JL.Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites..Proc Nat Acad Sci USA1989;86:695-8 PMCID:PMC286540

[57] Kuruppu AI,Collins H,Thomas NR.An apoferritin-based drug delivery system for the tyrosine kinase inhibitor gefitinib..Adv Healthcare Mater2015;4:2816-21

[58] Breen AF,Turyanska L.Development of novel apoferritin formulations for antitumor benzothiazoles..Cancer Reports2019;

[59] Kim M,Jin KS,Jung S.pH-depedent structures of ferritin and apoferritin in solution: disassembly and reassembly..Biomacromolecules2011;12:1629-40

[60] Noonan EM,Yaffe MB,Samson LD.O6-Methylguanine DNA lesions induce an intra-S-phase arrest from which cells exit into apoptosis governed by early and late multi-pathway signalling network activation..Integr Biol (Camb)2012;4:1237-55 PMCID:PMC3574819

[61] Silber JR,Blank A.O6-Methylguanine-DNA methyltransferase in glioma therapy: promise and problems..Biochim Biophys Acta2012;1826:71-82 PMCID:PMC3340514

[62] Kurimoto T,Ogino I,Arakawa A.Effect of O6-methylguanine-DNA methyltransferase methylation in medulloblasoma..Mol Clin Oncol2017;7:1107-11 PMCID:PMC5740829

[63] Pollack IF,Sobol RW,Yates AJ.O6-Methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-045 cohort..J Clin Oncol2006;24:3431-7

[64] Rood BR,Cogen PH.Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma..Neuro-Oncology2004;6:200-7 PMCID:PMC1872000

[65] Bobbola MS,Ellenbogen RG,Geyer JR.O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics..Clin Cancer Res2001;7:613-9

[66] Grossman SA,Ruckdeschel JC,Moynihan T.Randomized prospective comparison of intraventricular methotrexate and thiotepa with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group..Journal of Clinical Oncology1993;11:3561-9

[67] Ishikawa E,Takano S,Nose T.Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of intradermally injected paraformaldehyde-fixed tumor vaccine in a rat intracranial brain tumor model..Cancer Sci2004;95:98-103

[68] Rustamzadeh E,Todhunter DA,Low WC.Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice..Int J Cancer2006;120:411-9

[69] Lewis O,Johnson D,Barua NU.Chronic, intermittent convection-enhanced delivery devices..J Neurosci Methods2015;259:47-56

[70] Jahangiri A,Flanigan PM,Aghi MK.Convectin-enhanced delivery in glioblastoma: a review of preclinical and clinical studies..J Neurosurg2017;126:191-200 PMCID:PMC5571827

[71] Hollingworth M,Wooley M,Gill S.DIPG-65. Preliminary experience of chronic intermittant convection ehnanced delivery of carboplatin and valporic acid for the treatment of diffuse intrinsic pontine glioma following radiation therapy..Neuro-Oncology2018;20:i62